SUPNSupernus Pharmaceuticals, Inc.

$3B

Q3 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$103M+28.1% YoY

Gross Profit

$99M95.9% margin

Operating Income

$37M36.4% margin

Net Income

$28M27.2% margin

EPS (Diluted)

$0.52

QoQ Revenue Growth

+3.5%

Cash Flow

Operating Cash Flow

$62M

Free Cash Flow

$62M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$923M

Total Liabilities

$501M

Stockholders' Equity

$422M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$103M	$80M	+28.1%
Gross Profit	$99M	$76M	+29.7%
Operating Income	$37M	$22M	+67.7%
Net Income	$28M	$16M	+75.5%

Revenue Segments

Product

$100M49%

Trokendi X R

$80M39%

Oxtellar X R

$20M10%

Royalty

$3M1%

SUPN Q3 2018 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena